Trial Profile

A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Paclitaxel
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

Most Recent Events

05 May 2022 Status changed from active, no longer recruiting to completed.
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
15 Apr 2020 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com